DARU-Journal of Pharmaceutical Sciences

Papers
(The H4-Index of DARU-Journal of Pharmaceutical Sciences is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Short and long term impacts of COVID-19 on the pharmaceutical sector124
Therapeutic application of Carica papaya leaf extract in the management of human diseases57
Surging trends in prescriptions and costs of antidepressants in England amid COVID-1952
Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis42
A new sesquiterpenoid from the shoots of Iranian Daphne mucronata Royle with selective inhibition of STAT3 and Smad3/4 cancer-related signaling pathways39
A review of the hepatoprotective effects of hesperidin, a flavanon glycoside in citrus fruits, against natural and chemical toxicities34
COVID-19 vaccines: ethical framework concerning human challenge studies32
Fabrication, characterization and optimization of berberine-loaded PLA nanoparticles using coaxial electrospray for sustained drug release30
Stabilized oral nanostructured lipid carriers of Adefovir Dipivoxil as a potential liver targeting: Estimation of liver function panel and uptake following intravenous injection of radioiodinated indi28
Bibenzyls and bisbybenzyls of bryophytic origin as promising source of novel therapeutics: pharmacology, synthesis and structure-activity27
COVID-19 and off label use of drugs: an ethical viewpoint24
Polyherbal combination for wound healing: Matricaria chamomilla L. and Punica granatum L.21
Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review20
HSA-curcumin nanoparticles: a promising substitution for Curcumin as a Cancer chemoprevention and therapy18
Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition18
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir18
Design, synthesis, molecular docking study, and antibacterial evaluation of some new fluoroquinolone analogues bearing a quinazolinone moiety16
0.067157030105591